IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.45

Change

-0.16 (-0.23)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.81 (-0.53%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

-0.46 (-0.63%)

USD 2.97B
FXH First Trust Health Care AlphaD..

-1.05 (-0.94%)

USD 1.29B
PPH VanEck Pharmaceutical ETF

-0.49 (-0.52%)

USD 0.72B
XHE SPDR® S&P Health Care Equipme..

-2.02 (-2.23%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.15 (-0.63%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.19 (+0.51%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-1.90 (-1.96%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.39 (-1.32%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.71 (-1.13%)

USD 0.02B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.00% 91% A- 68% D+
Dividend Return 1.50% 94% A 29% F
Total Return 15.50% 95% A 65% D
Trailing 12 Months  
Capital Gain 21.65% 64% D 56% F
Dividend Return 1.84% 95% A 25% F
Total Return 23.49% 68% D+ 51% F
Trailing 5 Years  
Capital Gain 52.25% 55% F 70% C-
Dividend Return 8.72% 89% A- 27% F
Total Return 60.96% 64% D 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.38% N/A N/A 59% D-
Dividend Return 7.74% N/A N/A 56% F
Total Return 1.36% N/A N/A 32% F
Risk Return Profile  
Volatility (Standard Deviation) 11.19% N/A N/A 75% C
Risk Adjusted Return 69.20% N/A N/A 83% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike